$17.80
1.529.34%
À la clôture: Nov 17, 4:00 PM EST
$17.80
1.529.34%
Pré-ouverture: 7:00 AM EST

The average analyst price target for Apnimed is $50.33, 182.8% above the current price. Of 4 analysts, 4 rate it Buy. Targets range from $41 to $60. The latest change came on Aug 25, 2026, when LifeSci Capital initiated coverage of Apnimed with an Outperform rating and a $50 price target.
Price Target Range — 1 Quarters
Analyst Consensus — 4 Analysts
Rating Trend — Last 9 Months